What specific measures is Vaxart implementing to meet the Nasdaq Bid Price Rule by the Oct 17, 2025 deadline?

Vaxart’s filing with Nasdaq simply states that the company has been granted an extension to bring its share price back above the $1‑minimum required by the Nasdaq Bid‑Price Rule by October 17, 2025. The press release does not list concrete actions the company will take, but in situations like this biotech issuers typically resort to one or more of the following levers: a reverse stock split to boost the per‑share price, a share‑repurchase program (if cash permits) to reduce the float, or a focused operational turnaround that drives revenue and cash‑flow growth, thereby lifting market sentiment and price. Management’s recent commentary about advancing its oral vaccine pipeline and securing additional financing suggests they are betting on stronger fundamentals to support a price rally, while a reverse split remains the most direct way to satisfy the rule if the market price stays below $1 for an extended period.

From a trading standpoint, the key catalyst to watch is any formal announcement of a reverse split—historically such moves trigger a short‑term price bounce as the ticker adjusts and institutional investors re‑evaluate eligibility. Until then, the stock’s technical profile remains bearish: it has been trading below the $1 threshold, showing limited upside on the daily chart and a lack of buying pressure. Short‑term traders might consider tight‑stop longs on any breakout above $1 on volume, while risk‑averse investors may stay on the sidelines or hedge exposure given the lingering delisting risk. Long‑term investors should monitor Vaxart’s clinical milestones and financing activity; successful data readouts could organically lift the price and make a reverse split unnecessary, thereby improving the odds of compliance without further dilution.